SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00695-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von E B M Breidenstein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Summit Therapeutics, The Works, Unity Campus , Cambridge, United Kingdom. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIEHS NIH HHS.
Abstract (Originalsprache)
Carbapenem-resistant Enterobacteriaceae (CREs) are described by the Centers for Disease Control as an urgent threat, and there is a critical need for new therapeutic agents able to treat infections caused by these pathogens. Herein, we describe the microbiological profile, the mechanism f action, and the in vitro safety as well as the pharmacokinetic (PK)/PD profile of SMT-738, a small molecule belonging to a new chemical class. SMT-738 is active against Enterobacterales [including multi-drug-resistant Escherichia coli with 90% of isolates having a minimum inhibitory concentration (MIC 90 ) of 1 µg/mL and Klebsiella pneumoniae 2 µg/mL] and inactive against a broad panel of Gram-negative and Gram-positive pathogens. SMT-738 displays rapid bactericidal activity (2–4 h) and has a low propensity for resistance development (less than ~10 −9 ). Characterization of resistant mutants following exposure to SMT-738 identified mutations within the lipoprotein transport complex (LolCDE), a clinically unexploited and essential bacterial molecular target in Gram-negative bacteria. SMT-738 has a promising in vitro toxicology profile. Furthermore, PK studies demonstrated that when dosed intravenously, SMT-738 maintained exposure levels across infection sites (bloodstream/urinary tract/lung). Proof-of-concept studies across multiple murine in vivo infection models (bloodstream/pneumonia/urinary tract) demonstrated that SMT-738 significantly reduced the bacterial burden compared to baseline and vehicle control. SMT-738 represents a promising novel drug candidate being developed to address clinically challenging serious life-threatening infections caused by highly resistant Enterobacteriaceae including CRE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Summit Therapeutics, The Works, Unity Campus , Cambridge, United Kingdom.
- Summit Therapeutics , Menlo Park, California, USA.
ORCID-Profile: E B M Breidenstein, C-M Li, C S Mason
Förderung
- Wellcome Trust
- NIEHS NIH HHS
Zitieren
APA
Breidenstein, E. B. M., Khan, N., Duffy, T., Coward, C., Avis, T., Abdulle, O., Li, C. M., & Mason, C. S. (2024). SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00695-23
Vancouver
Breidenstein EBM, Khan N, Duffy T, Coward C, Avis T, Abdulle O, et al. SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00695-23
BibTeX
@article{Breidenstein2024,
author = {Breidenstein, E B M and Khan, N and Duffy, T and Coward, C and Avis, T and Abdulle, O and Li, C-M and Mason, C S},
title = {SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00695-23}
}
EUVIMED